The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, United States
Cancer Research (Impact Factor: 9.28). 01/2007; 66(23):11331-40. DOI: 10.1158/0008-5472.CAN-06-1540
Source: PubMed

ABSTRACT The collagen type IV cleavage fragment tumstatin and its active subfragments bind to integrin alpha(V)beta(3) and inhibit activation of focal adhesion kinase, phophoinositol-3 kinase, Akt, and mammalian target of rapamycin (mTOR) in what is thought to be an endothelial cell-specific manner. The resultant endothelial cell apoptosis accounts for the ability of tumstatin to function as an endogenous inhibitor of angiogenesis and an indirect suppressor of tumor growth. We hypothesized that the inability of tumstatin to directly suppress tumor cell growth might be the result of the constitutive activation of the Akt/mTOR pathway commonly seen in tumors. Consistent with this idea, several integrin alpha(V)beta(3)-expressing glioma cell lines with PTEN mutations and high levels of phospho-Akt (pAkt) were unaffected by exposure to an active fragment of tumstatin (T3), whereas alpha(V)beta(3)-expressing glioma cell lines with a functional PTEN/low levels of pAkt exhibited T3-induced growth suppression that could be bypassed by small interfering RNA-mediated suppression of PTEN, introduction of a constitutively expressed Akt, or introduction of the Akt and mTOR target eukaryotic translation initiation factor 4E. The direct tumor-suppressive actions of T3 were further shown in an alpha(V)beta(3)-deficient in vivo mouse model in which T3, while unable to alter the tumstatin-insensitive vasculature contributed by the alpha(V)beta(3)-deficient host, nonetheless suppressed the growth and proliferative index of i.c. implanted alpha(V)beta(3)-expressing PTEN-proficient glioma cells. These results show that tumstatin, previously considered to be only an endogenous inhibitor of angiogenesis, also directly inhibits the growth of tumors in a manner dependent on Akt/mTOR activation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite recent advances in molecular classification, surgery, radiotherapy, and targeted therapies, the clinical outcome of patients with malignant brain tumors remains extremely poor. In this study, we have identified the tetraspan protein epithelial membrane protein-2 (EMP2) as a potential target for glioblastoma (GBM) killing. EMP2 had low or undetectable expression in normal brain, but was highly expressed in GBM as 95% of patients showed some expression of the protein. In GBM cells, EMP2 enhanced tumor growth in vivo in part by upregulating αvβ3 integrin surface expression, activating FAK and Src kinases, and promoting cell migration and invasion. Consistent with these findings, EMP2 expression significantly correlated with activated Src kinase in patient samples and promoted tumor cell invasion using intracranial mouse models. As a proof of principle to determine if EMP2 could serve as a target for therapy, cells were treated using specific anti-EMP2 antibody reagents. These reagents were effective in killing GBM cells in vitro and in reducing tumor load in subcutaneous mouse models. These results support the role of EMP2 in the pathogenesis of GBM and suggest that anti-EMP2 treatment may be a novel therapeutic treatment.
    Journal of Biological Chemistry 03/2014; 289(20). DOI:10.1074/jbc.M113.543728 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor microenvironment is a complex system composed of a largely altered extracellular matrix with different cell types that determine angiogenic responses and tumor progression. Upon the influence of hypoxia, tumor cells secrete cytokines that activate stromal cells to produce proteases and angiogenic factors. In addition to stromal ECM breakdown, proteases exert various pro- or anti-tumorigenic functions and participate in the release of various ECM fragments, named matrikines or matricryptins, capable to act as endogenous angiogenesis inhibitors and to limit tumor progression. We will focus on the matrikines derived from the NC1 domains of the different constitutive chains of basement membrane-associated collagens and mainly collagen IV. The putative targets of the matrikine control are the proliferation and invasive properties of tumor or inflammatory cells, and the angiogenic and lymphangiogenic responses. Collagen-derived matrikines such as canstatin, tumstatin or tetrastatin for example, decrease tumor growth in various cancer models. Their anti-cancer activities comprise anti-proliferative effects on tumor or endothelial cells by induction of apoptosis or cell cycle blockade and the induction of a loss of their migratory phenotype. They were used in various preclinical therapeutic strategies: i) induction of their overexpression by cancer cells or by the host cells, ii) use of recombinant proteins or synthetic peptides or structural analogues designed from the structure of the active sequences, iii) used in combined therapies with conventional chemotherapy or radiotherapy. Collagen-derived matrikines strongly inhibited tumor growth in many preclinical cancer models in mouse. They constitute a new family of anticancer agents able to limit cancer progression.
    Biochimica et Biophysica Acta 01/2014; 1840(8). DOI:10.1016/j.bbagen.2013.12.029 · 4.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperglycemia stimulates secretion of αVβ3 ligands from vascular cells including endothelial cells resulting in activation of the αVβ3 integrin. This study determined if blocking ligand occupancy of αVβ3 would inhibit the development of diabetic nephropathy. Ten diabetic pigs received an F(ab)2 fragment of an antibody directed against the extracellular domain of the β3 subunit and ten received a control IgG F(ab)2 for 18 weeks. Non-diabetic pigs excreted 115 ± 50 μg of protein/mg creatinine compared to control F(ab)2 treated diabetic animals (218± 57 μg/mg) whereas diabetic animals treated with the anti-β3 F(ab)2 excreted 119 ± 55 μg/mg (p<0.05). Mesangial volume/glomerular volume increased to 21 ± 2.4 in control treated diabetic animals compared to 14 ± 2.8% (p<0.01) in animals treated with active antibody. Diabetic animals treated with control F(ab)2 had significantly less glomerular podocin staining compared to nondiabetic animals and this decrease was attenuated by treatment with anti-β3 F(ab)2. Glomerular basement membrane thickness was increased in the control, F(ab)2 treated diabetic animals (212±14 nm) compared to nondiabetic animals (170 ± 8.8 nm) but it was unchanged (159.9 ± 16.4 nm) in animals receiving anti-β3 F(ab)2. Podocyte foot process width was greater in control, F(ab)2 treated, animals (502± 34 nm) compared to animals treated with the anti-β3 F(ab)2 (357±47 nm, p<0.05). Renal β3 tyrosine phosphorylation decreased from 13,934 ± 6437 to 6730 ± 1524 (p<0.01) scanning units in the anti-β3 treated group. We conclude that administration of an antibody that inhibits activation of the β3 subunit of αVβ3 that is induced by hyperglycemia attenuates proteinuria and early histologic changes of diabetic nephropathy suggesting that it may have utility in preventing the progression of this disease complication.
    Endocrinology 08/2014; 155(12):en20141318. DOI:10.1210/en.2014-1318 · 4.64 Impact Factor